Skip to main content

Advertisement

Table 1 Studies of the viral population of HIV-1 infected infants

From: The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Infant samples Infection route Homo-/heterogeneous population ratio References
Nature Collection time* Amplified envregion
PBMCs 2 to 4 months V3 and V4-V5 Unspecified 3/0 [61]
PBMCs Unspecified V3 and V4-V5 Unspecified 4/0 [68]
PBMCs and serum 0 to 4 months V3 1 IU, 9 unknown 8 (1 IU)/2 [69]
Serum At birth V3 1 IU 1/0 [70]
PBMCs 0 to 12.5 months V3 1 IU, 4 unknown 2/3 (1 IU) [71]
PBMCs 2 days to 7 weeks V1-V2-C2 Unspecified 1/2 [72]
PBMCs 1 week to 34 months V3 Unspecified 7/0 [73]
PBMCs 5 days to 1.5 months V3 Probably 1 PN, 3 IU 1 (PN)/3 (IU) [74]
PBMCs and plasma 2 to 40 days C2-V3 Unspecified 3/1 [75]
PBMCs 1 month V3 Unspecified 13/4 [76]
Plasma 48 hours or 2 to 6 weeks V3-V5 9 PN, 14 IU 17 (7 PN, 10 IU)/6 (2 PN, 4 IU) [77]
PBMCs 0 or 2 to 6 months C2-V4 3 PN or early PP, 1 IU 3 (2 PN, 1 IU)/1 [78]
PBMCs 0 or 6 weeks V1-V4 7 PN or early PP, 6 IU 6 (2 IU, 4 PN)/7 (4 IU, 3 PN) [79]
PBMCs 48 hours or 2 to 6 weeks V3-V5 7 PN, 14 IU 15 (5 PN, 10 IU)/6 (2 PN, 4 IU) [80]
PBMCs or plasma 6 weeks V1-V5 8 PN or early PP, 1 IU, 3 BF 11/1 (PN) [81]
PBMCs or cord blood 0 or 6 to 15 months V1-V3 3 PP, 1 IU 4/0 [82]
PBMCs 4 to 18 months V1-V5 Unspecified 0/3 [83]
Plasma 0 or 6 weeks V1-V2 23 PN, 25 IU 20 (6 PN, 14 IU)/28 (17 PN, 11 IU) [84]
Plasma 48 hours or 6 weeks V1-V5 11 PN, 6 IU 14 (9 PN, 5 IU)/3 (2 PN, 1 IU) [85]
PBMCs 2 to 4 months V1-V5 6 PN or early PP 5/1 [86]
Plasma 30 to 66 days V1-V5 5 PN 3/2 [87]
Plasma 0 or 6 weeks V1-V5 9 PN or early PP, 10 IU 13 (5 PN, 8 IU)/6 (4 PN, 2 IU) [88]
Plasma 3 or 6 months complete env 2 PP 2/0 [89]
     total: 156/235  
  1. * Time of the first PCR or coculture positive collected sample after birth.
  2. PN: perinatally; IU: in utero; PP: postpartum through breastfeeding.